Drugs & Targets FDA accepts BLA for Tevimbra for 1L treatment of G/GEJ cancers March 01, 2024Vol.50 No.09
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Conversation with The Cancer Letter Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
In Brief House Energy and Commerce Committee Democratic leaders urge FDA to advance clinical trial diversity efforts February 23, 2024Vol.50 No.08
Drugs & Targets Linvoseltamab BLA accepted for Priority Review for R/R multiple myeloma February 23, 2024Vol.50 No.08
Drugs & Targets FDA OCE annual report lists 83 cancer therapeutic approvals in 2023 February 23, 2024Vol.50 No.08
Drugs & Targets FDA approves Onivyde for first-line treatment of metastatic pancreatic adenocarcinoma February 16, 2024Vol.50 No.07
Drugs & Targets FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors February 16, 2024Vol.50 No.07
